文献速递泌尿男性生殖肿瘤

177Lu-Lu-PSMA-617联合标准治疗对比标准治疗在转移性去势抵抗性前列腺癌患者中的健康相关生活质量与疼痛结局(VISION):一项多中心、开放标签、随机、3期试验

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2023-01-01

VISION试验在北美和欧洲84个癌症中心纳入831例患者,其中581例(177Lu组385例,对照组196例)纳入生活质量、疼痛和症状性骨骼事件分析。与单纯标准治疗相比,177Lu-Lu-PSMA-617联合标准治疗延迟了FACT-P评分、BPI-SF疼痛强度评分和EQ-5D-5L效用评分的恶化时间,并延长了至首次症状性骨骼事件或死亡的时间。

要点

  • 177Lu组至首次症状性骨骼事件或死亡的中位时间为11.5个月,对照组为6.8个月(HR 0.50)。
  • 177Lu组FACT-P评分恶化风险低于对照组(HR 0.54),BPI-SF疼痛强度评分(HR 0.52)和EQ-5D-5L效用评分(HR 0.65)恶化风险亦较低。
  • 177Lu组3-4级血液学不良事件(血红蛋白下降、淋巴细胞减少、血小板减少)发生率高于对照组。

核心结论

  • 在转移性去势抵抗性前列腺癌患者中,177Lu-Lu-PSMA-617联合标准治疗较单纯标准治疗延迟了健康相关生活质量和疼痛的恶化时间,并延迟了至骨骼事件的时间。

研究设计与样本

  • 多中心、开放标签、随机、3期试验,在北美和欧洲九个国家84个癌症中心开展。
  • 患者按2:1随机分配至177Lu-Lu-PSMA-617联合标准治疗组或单纯标准治疗组,随机化按基线乳酸脱氢酶浓度、肝转移、ECOG体能状态和标准治疗中是否包含雄激素受体通路抑制剂分层。
  • 患者报告结局和症状性骨骼事件在2019年3月5日及之后随机分配的所有患者中分析(共581例:177Lu组385例,对照组196例)。

主要发现

  • 至首次症状性骨骼事件或死亡的中位时间:177Lu组11.5个月(95%CI 10.3-13.2),对照组6.8个月(95%CI 5.2-8.5),HR 0.50(95%CI 0.40-0.62)。
  • FACT-P评分恶化时间:HR 0.54(95%CI 0.45-0.66),177Lu组较对照组延迟。
  • BPI-SF疼痛强度评分恶化时间:HR 0.52(95%CI 0.42-0.63),177Lu组较对照组延迟。
  • EQ-5D-5L效用评分恶化时间:HR 0.65(95%CI 0.54-0.78),177Lu组较对照组延迟。
  • 3-4级血液学不良事件:血红蛋白下降177Lu组80例(15%)/529例可评估患者 vs 对照组13例(6%)/205例;淋巴细胞减少269例(51%)vs 39例(19%);血小板减少49例(9%)vs 5例(2%)。

关键数值与推荐

  • 177Lu-Lu-PSMA-617用法:每6周静脉输注7.4 GBq(200 mCi),共4个周期,另可选2个额外周期。
  • 标准治疗包括已批准的激素治疗、双膦酸盐和放疗。
  • 治疗相关不良事件导致死亡:177Lu组5例(1%)(全血细胞减少2例、骨髓衰竭1例、硬膜下血肿1例、颅内出血1例),对照组0例。

临床怎么用

  • 作者认为,这些发现支持在既往接受过雄激素受体通路抑制剂和紫杉类治疗的转移性去势抵抗性前列腺癌患者中使用177Lu-Lu-PSMA-617。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In VISION, the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium-177 [177Lu]Lu-PSMA-617 (vipivotide tetraxetan) improved radiographic progression-free survival and overall survival when added to protocol-permitted standard of care in patients with metastatic castration-resistant prostate cancer. Here, we report additional health-related quality of life (HRQOL), pain, and symptomatic skeletal event results. METHODS: This multicentre, open-label, randomised, phase 3 trial was conducted at 84 cancer centres in nine countries in North America and Europe. Eligible patients were aged 18 years or older; had progressive PSMA-positive metastatic castration-resistant prostate cancer; an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; and had previously received of at least one androgen receptor pathway inhibitor and one or two taxane-containing regimens. Patients were randomly assigned (2:1) to receive either [177Lu]Lu-PSMA-617 plus protocol-permitted standard of care ([177Lu]Lu-PSMA-617 group) or standard of care alone (control group) using permuted blocks. Randomisation was stratified by baseline lactate dehydrogenase concentration, liver metastases, ECOG performance status, and androgen receptor pathway inhibitor inclusion in standard of care. Patients in the [177Lu]Lu-PSMA-617 group received intravenous infusions of 7·4 gigabecquerel (GBq; 200 millicurie [mCi]) [177Lu]Lu-PSMA-617 every 6 weeks for four cycles plus two optional additional cycles. Standard of care included approved hormonal treatments, bisphosphonates, and radiotherapy. The alternate primary endpoints were radiographic progression-free survival and overall survival, which have been reported. Here we report the key secondary endpoint of time to first symptomatic skeletal event, and other secondary endpoints of HRQOL assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and EQ-5D-5L, and pain assessed with the Brief Pain Inventory-Short Form (BPI-SF). Patient-reported outcomes and symptomatic skeletal events were analysed in all patients who were randomly assigned after implementation of measures designed to reduce the dropout rate in the control group (on or after March 5, 2019), and safety was analysed according to treatment received in all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov, NCT03511664, and is active but not recruiting. FINDINGS: Between June 4, 2018, and Oct 23, 2019, 831 patients were enrolled, of whom 581 were randomly assigned to the [177Lu]Lu-PSMA-617 group (n=385) or control group (n=196) on or after March 5, 2019, and were included in analyses of HRQOL, pain, and time to first symptomatic skeletal event. The median age of patients was 71 years (IQR 65-75) in the [177Lu]Lu-PSMA-617 group and 72·0 years (66-76) in the control group. Median time to first symptomatic skeletal event or death was 11·5 months (95% CI 10·3-13·2) in the [177Lu]Lu-PSMA-617 group and 6·8 months (5·2-8·5) in the control group (hazard ratio [HR] 0·50, 95% CI 0·40-0·62). Time to worsening was delayed in the [177Lu]Lu-PSMA-617 group versus the control group for FACT-P score (HR 0·54, 0·45-0·66) and subdomains, BPI-SF pain intensity score (0·52, 0·42-0·63), and EQ-5D-5L utility score (0·65, 0·54-0·78). Grade 3 or 4 haematological adverse events included decreased haemoglobin (80 [15%] of 529 assessable patients who received [177Lu]Lu-PSMA-617 plus standard of care vs 13 [6%] of 205 who received standard of care only), lymphocyte concentrations (269 [51%] vs 39 [19%]), and platelet counts (49 [9%] vs five [2%]). Treatment-related adverse events leading to death occurred in five (1%) patients who received [177Lu]Lu-PSMA-617 plus standard of care (pancytopenia [n=2], bone marrow failure [n=1], subdural haematoma [n=1], and intracranial haemorrhage [n=1]) and no patients who received standard of care only. INTERPRETATION: [177Lu]Lu-PSMA-617 plus standard of care delayed time to worsening in HRQOL and time to skeletal events compared with standard of care alone. These findings support the use of [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer who received previous androgen receptor pathway inhibitor and taxane treatment. FUNDING: Advanced Accelerator Applications (Novartis).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Fizazi K, Herrmann K, Krause BJ, et al. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023. PMID: 37269841. doi:10.1016/S1470-2045(23)00158-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。